DTIL - Precision BioSciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Durham,
United States
Type: Equity
DTIL price evolution
DTIL
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $123.57 | $137.77 | $116.68 | |
| Short term investments | $12.25 | $11.55 | $11.9 | |
| Net receivables | $1.55 | $0.21 | $0.39 | $0.9 |
| Inventory | ||||
| Total current assets | $110.52 | $144.03 | $160.83 | $136.36 |
| Long term investments | $9.24 | $10.02 | $8.2 | |
| Property, plant & equipment | $10.96 | $11.92 | $13.27 | $14.6 |
| Goodwill & intangible assets | $0.38 | $0.39 | $0.4 | |
| Total noncurrent assets | $21.77 | $23.91 | $23.42 | |
| Total investments | $21.49 | $21.58 | $20.09 | |
| Total assets | $153.26 | $165.8 | $184.74 | $159.78 |
| Current liabilities | ||||
| Accounts payable | $0.96 | $23.64 | $23.6 | $25.38 |
| Deferred revenue | $37.31 | $87.17 | $95.12 | |
| Short long term debt | $1.22 | $1.18 | $1.13 | |
| Total current liabilities | $11.98 | $32.96 | $33.34 | $49.99 |
| Long term debt | $22.28 | $7.09 | $7.41 | $7.72 |
| Total noncurrent liabilities | $58.13 | $114.2 | $90.93 | |
| Total debt | $8.31 | $8.59 | $8.86 | |
| Total liabilities | $88.39 | $91.09 | $147.53 | $140.92 |
| Shareholders' equity | ||||
| Retained earnings | -$464.72 | -$448.29 | -$481.04 | -$489.63 |
| Other shareholder equity | ||||
| Total shareholder equity | $74.71 | $37.21 | $18.86 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $116.68 | $189.58 | $143.66 | $89.8 |
| Short term investments | $11.9 | |||
| Net receivables | $0.9 | $0.72 | $0.49 | $10 |
| Inventory | ||||
| Total current assets | $136.36 | $199.1 | $161.75 | $105.56 |
| Long term investments | $8.2 | $11.98 | $13.72 | |
| Property, plant & equipment | $14.6 | $23.16 | $29.33 | $41.5 |
| Goodwill & intangible assets | $0.4 | $1.35 | $2.05 | $1.37 |
| Total noncurrent assets | $23.42 | $39.06 | $49.74 | $44.59 |
| Total investments | $20.09 | $11.98 | $13.72 | |
| Total assets | $159.78 | $238.17 | $211.5 | $150.16 |
| Current liabilities | ||||
| Accounts payable | $25.38 | $1.23 | $1.14 | $0.79 |
| Deferred revenue | $95.12 | $139.06 | $98.26 | $84.16 |
| Short long term debt | $1.13 | $2.04 | $1.82 | $1.93 |
| Total current liabilities | $49.99 | $59.66 | $35.98 | $42.83 |
| Long term debt | $7.72 | $22.22 | $7.29 | $8.59 |
| Total noncurrent liabilities | $90.93 | $118.07 | $84.35 | $62.9 |
| Total debt | $8.86 | $27.04 | $9.11 | $10.52 |
| Total liabilities | $140.92 | $177.74 | $120.33 | $105.73 |
| Shareholders' equity | ||||
| Retained earnings | -$489.63 | -$428.31 | -$316.68 | -$286.07 |
| Other shareholder equity | -$0 | $0.05 | ||
| Total shareholder equity | $18.86 | $60.43 | $91.17 | $44.42 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.58 | $49.9 | $17.58 | $7.04 |
| Cost of revenue | ||||
| Gross Profit | $49.9 | $17.58 | $7.04 | |
| Operating activities | ||||
| Research & development | $17.23 | $13.34 | $13.39 | |
| Selling, general & administrative | $8.53 | $8.43 | $8.54 | |
| Total operating expenses | $21.85 | $25.75 | $21.77 | $21.93 |
| Operating income | $24.15 | -$4.19 | -$14.89 | |
| Income from continuing operations | ||||
| EBIT | $33.31 | $9.16 | -$15.71 | |
| Income tax expense | ||||
| Interest expense | $1.2 | $0.56 | $0.57 | $0.58 |
| Net income | ||||
| Net income | -$16.43 | $32.75 | $8.59 | -$16.29 |
| Income (for common shares) | $32.75 | $8.59 | -$16.29 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $48.73 | $25.1 | $115.53 | $24.29 |
| Cost of revenue | ||||
| Gross Profit | $48.73 | $25.1 | $115.53 | $24.29 |
| Operating activities | ||||
| Research & development | $53.38 | $83.94 | $115.24 | $98.06 |
| Selling, general & administrative | $39.09 | $41.52 | $39.69 | $36.05 |
| Total operating expenses | $92.46 | $125.46 | $154.93 | $134.11 |
| Operating income | -$43.74 | -$100.37 | -$39.4 | -$109.83 |
| Income from continuing operations | ||||
| EBIT | -$59.09 | -$110.53 | -$30.47 | -$109.01 |
| Income tax expense | ||||
| Interest expense | $2.23 | $1.11 | $0.13 | |
| Net income | ||||
| Net income | -$61.32 | -$111.64 | -$30.6 | -$109.01 |
| Income (for common shares) | -$61.32 | -$111.64 | -$30.6 | -$109.01 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $32.75 | $8.59 | -$16.29 | |
| Operating activities | ||||
| Depreciation | $1.38 | $1.43 | $1.56 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.93 | $2.91 | $2.97 | |
| Total cash flows from operations | -$14.87 | -$18.98 | -$8.42 | |
| Investing activities | ||||
| Capital expenditures | -$0.03 | -$0.03 | $0.06 | |
| Investments | ||||
| Total cash flows from investing | -$0.12 | -$0.03 | -$0.03 | $0.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.7 | $40.09 | $2.83 | |
| Net borrowings | ||||
| Total cash flows from financing | $44.53 | $0.7 | $40.09 | $2.83 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $4.65 | -$14.2 | $21.09 | -$5.55 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$61.32 | -$111.64 | -$30.6 | -$109.01 |
| Operating activities | ||||
| Depreciation | $8.26 | $9 | $10.2 | $9.81 |
| Business acquisitions & disposals | $8 | |||
| Stock-based compensation | $14.04 | $19.2 | $16.51 | $13.79 |
| Total cash flows from operations | -$84.11 | -$45.75 | -$10.85 | -$87.39 |
| Investing activities | ||||
| Capital expenditures | -$1.85 | -$3.32 | -$5.05 | -$5.03 |
| Investments | ||||
| Total cash flows from investing | $5.83 | -$3.32 | -$5.8 | -$5.03 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.39 | $74.79 | $68.06 | $1.33 |
| Net borrowings | $19.8 | $2.46 | ||
| Total cash flows from financing | $5.39 | $94.98 | $70.52 | $1.33 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$72.9 | $45.91 | $53.87 | -$91.09 |
News
Fundamentals
| Market cap | $42.64M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 7.48M |
| Revenue | $75.10M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $8.62M |
| Revenue Q/Q | -95.61% |
| Revenue Y/Y | 43.62% |
| P/E ratio | 4.94 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.57 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $1.15 |
|---|---|
| ROA | 5.20% |
| ROE | N/A |
| Debt/Equity | 7.47 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 9.22 |
| Quick ratio | N/A |